A. Healthcare professionals should be aware that postmarketing cases of severe liver injury have been reported rarely with the use of orlistat. They should weigh the benefits of weight-loss with the potential risks associated with Xenical and Alli before prescribing or recommending these medications to their patients.
• Know that organic causes of obesity should be ruled out before therapy starts.
• Give three times daily with meal containing fat (Alli) or up to 1 hour after a meal (Xenical).
• If patient misses a meal or eats a fat-free meal, omit dose.
• Know that orlistat therapy is frequently combined with psychotherapy.
|Orlistat is generic Xenical tablet and is proven to be one of the best weight loss medicines available online.|
A. FDA advises patients who are concerned about their use of prescription or over-the-counter orlistat to discuss those concerns with their healthcare professionals. People should continue to take Xenical as directed on the prescription label, and follow the directions for use on the Drug Facts box for Alli. In addition, they should stop use of orlistat and contact their healthcare professional if they develop itching, yellow eyes or skin, dark urine, light-colored stools, or loss of appetite. These may be signs of a serious condition such as liver injury.
The safety and efficacy of XENICAL have been evaluated in obese adolescent patients aged 12 to 16 years. Use of XENICAL in this age group is supported by evidence from adequate and well-controlled studies of XENICAL in adults with additional data from a 54-week efficacy and safety study and a 21-day mineral balance study in obese adolescent patients aged 12 to 16 years. Patients treated with XENICAL had a mean reduction in BMI of 0.55 kg/mcompared with an average increase of 0.31 kg/min placebo-treated patients (p=0.001). In both adolescent studies, adverse effects were generally similar to those described in adults and included fatty/oily stool, oily spotting, and oily evacuation. In a subgroup of 152 orlistat and 77 placebo patients from the 54-week study, changes in body composition measured by DEXA were similar in both treatment groups with the exception of fat mass, which was significantly reduced in patients treated with XENICAL compared to patients treated with placebo (-2.5 kg vs -0.6 kg, p=0.033). Because XENICAL can interfere with the absorption of fat-soluble vitamins, all patients should take a daily multivitamin that contains vitamins A, D, E, K, and beta-carotene. The supplement should be taken at least 2 hours before or after XENICAL (see ). XENICAL has not been studied in pediatric patients below the age of 12 years.